R Donald Harvey III PharmD


Other Affiliations:

No affiliations have been saved.

External Links (e.g. Departmental web site, iTunes lectures, etc.):

No external links have been saved.

Degrees Held:

No degrees have been saved.

Research Interests:

No research interests have been saved.

Biography/Description of Research:

No biography information has been saved.

Works 1-10 of 36

  1. 1
  2. 2
  3. 3
  4. 4


A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies

by R. Harvey; Taofeek Owonikoko; C M Lewis; A Akintayo; Z Chen; M Tighiouart; Suresh Ramalingam; MP Fanucchi; P Nadella; A Rogatko; Dong Shin; Bassel El-Rayes; FR Khuri; JS Kauh



Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

by R. Harvey; ARA Razak; JM Cleary; V Moreno; M Boyer; E Calvo Aller; W Edenfield; J Tie; A Rutten; MA Shah; AJ Olszanski; D Jäger; N Lakhani; DP Ryan; E Rasmussen; G Juan; H Wong; N Soman; MAD Smit; D Nagorsen; KP Papadopoulos



Preventing and Managing Toxicities of High-Dose Methotrexate

by Scott C. Howard; John McCormick; Ching-Hon Pui; Randall K. Buddington; R Donald Harvey



A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

by KP Papadopoulos; Bassel El-Rayes; AW Tolcher; A Patnaik; DW Rasco; R Donald Harvey; PM LoRusso; JC Sachdev; G Abbadessa; RE Savage; T Hall; B Schwartz; Y Wang; J Kazakin; Walid Shaib



Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors

by Anthony J. Olszanski; David C. Smith; Luis H. Camacho; John Thompson; Suresh S Ramalingam; R Donald Harvey; Luis Campos; David Ferry; Shande Tang; Ling Gao; Howard Safran



Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

by Neeraj Gupta; Michael J. Hanley; Cindy Xia; Richard Labotka; R Donald Harvey; Karthik Venkatakrishnan



A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

by Hatem H. Soliman; Erica Jackson; Tony Neuger; E. Claire Dees; R. Harvey; Hyo Han; Roohi Ismail-Khan; Susan Minton; Nicholas N. Vahanian; Charles Link; Daniel M. Sullivan; Scott Antonia